Core Insights - Southbound funds increased their holdings in Baize Medical (02609.HK) by 800.16 million shares on September 19, 2025, marking a significant increase in investment interest [1] - Over the past five trading days, Baize Medical has seen a cumulative net increase of 61.66 million shares held by southbound funds, indicating strong demand [1] - As of now, southbound funds hold a total of 64.40 million shares of Baize Medical, representing 4.88% of the company's total issued ordinary shares [1] Trading Data Summary - On September 19, 2025, total shares held reached 64.40 million, with a change of 800.16 million shares, reflecting a 14.19% increase [2] - On September 18, 2025, total shares held were 56.40 million, with a change of 20.24 million shares, showing a 55.96% increase [2] - On September 17, 2025, total shares held were 36.16 million, with a change of 16.90 million shares, indicating an 87.75% increase [2] - On September 16, 2025, total shares held were 19.26 million, with a change of 16.29 million shares, representing a 547.44% increase [2] - On September 15, 2025, total shares held were 2.97 million, with a change of 0.24 million shares, reflecting an 8.66% increase [2] Company Overview - Baize Medical Group primarily engages in investment and provision of medical-related services, focusing on oncology care [2] - The company offers comprehensive oncology services, including screening, diagnosis, treatment, and rehabilitation [2] - Baize Medical's operations include hospital services, hospital management, supply of pharmaceuticals, medical devices, and consumables, as well as other health management services [2] - The company primarily operates in the Chinese market, providing services such as cancer diagnosis, treatment, rehabilitation, and end-of-life care [2]
佰泽医疗（02609.HK）：9月19日南向资金增持800.16万股